Drug
Ivacaftor clinical trials
Also written VX-770, Kalydeco and VX-561.
- studies test it
- 105
- open now
- 5
- in phase 3
- 52
- first study started
- 2007
Keep track of what changes. Save the ivacaftor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
105 studies that test it; most in 2016 (13)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 11 |
| 2014 | 3 |
| 2015 | 12 |
| 2016 | 13 |
| 2017 | 9 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 19
- Phase 2
- 24
- Phase 3
- 52
- Phase 4
- 8
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 89 · Other 16
Vertex Pharmaceuticals Incorporated (85) · University of Alabama at Birmingham (7) · Concert Pharmaceuticals (3) · Royal College of Surgeons, Ireland (1) · Istituto Auxologico Italiano (1) · Nottingham University Hospitals NHS Trust (1) · Parion Sciences (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Tezacaftor (44) · Elexacaftor (23) · Lumacaftor (16) · Olacaftor (2) · Ciprofloxacin (2) · Rifampin (2) · VX-828 (1) · Lumacaftor, ivacaftor drug combination (1)
Studies
Open first, then newest update. How each study uses ivacaftor is read from its arms, and is right about nine times in ten.
Testing it · 105
- Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisRecruitingPhase 1Vertex Pharmaceuticals IncorporatedNCT07283770Written as D-IVA
- Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic FibrosisRecruitingPhase 4Istituto Giannina GasliniNCT07809867Written as Elexacaftor, Tezacaftor, Ivacaftor
- Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsRecruitingPhase 1Vertex Pharmaceuticals IncorporatedNCT07437105Written as Deutivacaftor
- Ensuring Access to Optimal Therapy in CF: The ENACT StudyRecruitingPhase 4Arkansas Children's Hospital Research InstituteNCT07148739Written as Elexacaftor / Ivacaftor / Tezacaftor
- Ivacaftor for Acquired CFTR Dysfunction in Chronic RhinosinusitisRecruitingEarly Phase 1University of Alabama at BirminghamNCT03439865Written as Ivacaftor
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05882357Written as ELX/TEZ/IVA
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT05331183Written as ELX/TEZ/IVA
- Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)Active, not recruitingPhase 4Royal College of Surgeons, IrelandNCT04602468Written as Elexacaftor/Tezacaftor/Ivacaftor
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06154447Written as Deutivacaftor
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT06460506Written as ELX/TEZ/IVA
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05153317Written as ELX/TEZ/IVA
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525574Written as ELX/TEZ/IVA
- Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label ExpansionCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT02070744Written as Ivacaftor
- A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04969224Written as ELX/TEZ/IVA
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04183790Written as ELX/TEZ/IVA
- Mutation-specific Therapy for the Long QT SyndromeCompletedPhase 2Istituto Auxologico ItalianoNCT04581408Written as Lumacaftor / Ivacaftor, Orkambi® Oral Tablet
- Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon MutationsTerminatedPhase 4University of Alabama at BirminghamNCT03624101Written as Ivacaftor and Symdeko
- The Topic Trial - Study to Determine the Safety and Efficacy of IvacaftorCompletedPhase 2University of Alabama at BirminghamNCT03085485Written as Ivacaftor 150 MG
- A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03277196Written as IVA
- Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04235140Written as LUM/IVA
See all 105 studies that test ivacaftor →
Given in every arm · 12 — ivacaftor is usual care beside what is tested
- A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)CompletedPhase 1/2Vertex Pharmaceuticals IncorporatedNCT05668741Written as IVA
- A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CFActive, not recruitingPhase 2ReCode TherapeuticsNCT06237335Written as Ivacaftor
- A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleCompletedPhase 2Eloxx Pharmaceuticals, Inc.NCT04126473Written as Ivacaftor
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03912233Written as VX-561
- A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X AlleleCompletedPhase 2Eloxx Pharmaceuticals, Inc.NCT04135495Written as Ivacaftor
- A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyTerminatedPhase 3Vertex Pharmaceuticals IncorporatedNCT03447262Written as IVA
- A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525444Written as IVA
- A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03447249Written as IVA
- A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525548Written as TEZ/IVA
- A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03460990Written as TEZ/IVA
- A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR MutationTerminatedPhase 4Vertex Pharmaceuticals IncorporatedNCT02823470Written as LUM/IVA
- A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic FibrosisCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT03029455Written as Ivacaftor
As the comparator · 5 — what is tested is compared with ivacaftor
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05033080Written as ELX/TEZ/IVA
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05076149Written as ELX/TEZ/IVA
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03912233Written as VX-561
- A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525548Written as TEZ/IVA
- A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03460990Written as TEZ/IVA
Codes
What other systems call ivacaftor · ClinicalTrials.gg INT005526
- MeSH (NLM) C545203ivacaftorConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1Y740ILL1ZIVACAFTORConfirmed FDA, NLM, Wikidata
- RxNorm 1243041Confirmed FDA, Wikidata
- Wikidata Q6095693ivacaftorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166523IvacaftorOne source FDA
- DrugBank DB08820One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545203 | ivacaftor | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1Y740ILL1Z | IVACAFTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1243041 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6095693 | ivacaftor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166523 | Ivacaftor | One source FDA |
| DrugBank | DB08820 | — | One source Wikidata |
Also registered as deutivacaftor (UNII SHA6U5FJZL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.